Researchers reported a strategy to optimize CAR T-cell therapy by precisely modulating receptor affinity, aiming to balance antitumor efficacy with safety. The work frames receptor affinity as a tunable parameter that can shift both potency and toxicity profiles across patient-relevant contexts. Instead of treating CAR design as a one-dimensional optimization, the study describes a pathway for receptor engineering that can influence how CARs signal and how strongly they engage target antigens in vivo. The findings are positioned as a potential lever to improve outcomes in cancers where therapeutic windows are constrained. For the field, the study adds to a growing body of work on “safety-by-design” in cell therapy, including approaches that reduce on-target off-tumor activity or limit excessive signaling. It also provides rationale for how next-generation CAR constructs could be tailored beyond a single affinity setting. The report may inform platform decisions for future clinical batches, particularly as manufacturers move toward more modular CAR design workflows.